Introduction: In this retrospective study, we compared transverse short tau inversion recovery (STIR), transverse diffusion-weighted imaging (DWI), apparent diffusion coefficient (ADC) map and first post-contrast fat-saturated fast low-angle shot (FLASH) 3D T1 with pathology results in terms of their accuracy in estimating breast carcinoma size.
Methods: Magnetic resonance imaging data for 47 patients with invasive breast carcinoma, who were treated surgically, were reviewed. The longest dimension (LD) of the index lesion was measured using STIR, DWI, ADC map and first post-contrast FLASH 3D T1, and this was compared with the LD measured on the pathology specimen.
Results: All four MRI sequences overestimated the LD by an average of about 1 mm with 95% limits of agreement approximately 0 to 2 mm. This is not considered to be clinically significant in tumours of 10 mm or larger.
Conclusion: Magnetic resonance imaging serves as an accurate tool in sizing breast carcinomas. ADC may be a useful evaluation tool for sizing carcinomas without requiring contrast material.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1754-9485.12205 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhanced pharmacokinetic approach for anastrozole in macromolecule-based silk fibroin nanoparticles incorporated injectables for estrogen-positive breast cancer therapy.
J Drug Target
January 2025
Department of Pharmaceutics, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to be University), Mangalore, Karnataka, 575018, India.
Breast cancer (BC) is a substantial reason for cancer-related mortality among women across the globe. Anastrozole (ANS) is an effective orally administered hormonal therapy for estrogen+ (ER+) BC treatment. However, several side effects and pharmacokinetic limitations restricted its uses in BC treatment.
View Article and Find Full Text PDFAdenoid cystic carcinoma of the breast, from diagnosis to management: a case report.
J Med Case Rep
January 2025
Department of Pathology and Laboratories, University Hospital Fundación Santa Fe de Bogotá, Bogotá, DC, Colombia.
Background: Adenoid cystic carcinoma of the breast is a rare subtype, constituting less than 3.5% of primary breast carcinomas. Despite being categorized as a type of triple-negative breast cancer, it generally has a favorable prognosis.
View Article and Find Full Text PDFPNMA1 is a novel immune modulator and therapeutic target in hepatocellular carcinoma linked to bile acid metabolism.
Sci Rep
January 2025
Department of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Hepatocellular carcinoma (HCC) necessitates innovative prognostic biomarkers and therapeutic targets. By investigating PNMA1 in HCC via the TCGA and GEO databases and our clinical data, we found that its overexpression is associated with worse survival. The relevance of PNMA1 extends to immune factors such as M1 macrophages, CD8 T cells, and immune checkpoints.
View Article and Find Full Text PDFNew thiazole derivative as a potential anticancer and topoisomerase II inhibitor.
Sci Rep
January 2025
Chemistry Department, Faculty of Science, Damietta University, Damietta, New-Damietta, 34517, Egypt.
To shed light on the significance of thiazole derivatives in the advancement of cancer medication and to contribute to therapeutic innovation, we have designed the synthesis and antiproliferative activity investigation of 5-(1,3-dioxoisoindolin-2-yl)-7-(4-nitrophenyl)-2-thioxo-3,7-dihydro-2H-pyrano[2,3-d] thiazole-6-carbonitrile, the structure of thiazole derivative was confirmed by spectroscopic techniques UV, IR and NMR. The cytotoxic activity (in vitro) of the new hybrid synthesized compound on five human cancer cell lines; human liver hepatocellular carcinoma (HepG-2), colorectal carcinoma (HCT-116), breast adenocarcinoma (MCF-7), and epithelioid carcinoma (Hela), and a normal human lung fibroblast (WI-38) was studied using MTT assay. The compound exhibited a strong cytotoxicity effect against HepG-2 and MCF-7.
View Article and Find Full Text PDFPhase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients With Advanced Thymoma or Thymic Carcinoma.
Clin Lung Cancer
December 2024
Georgetown University, Washington, DC. Electronic address:
Background: Thymic epithelial tumors (TETs), including thymoma and thymic carcinoma, are rare thoracic tumors of the anterior mediastinum. For those with advanced disease, platinum-based chemotherapy is used as first-line treatment. However, there is no standard regimen established for TET at progression after initial therapy, and treatment options for advanced/recurrent TETs are limited.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!